amerihealth
Advanced Search

Chemical Peels
MA11.103c

Policy

This policy uses coverage criteria primarily based on applicable Medicare statutes, regulations, NCDs, LCDs, CMS manuals and other applicable Medicare coverage documents. In the absence of fully established coverage criteria from these Medicare coverage documents for a specific medical service or item, the criterion/indication/service indicated by an asterisk below (*) is based on internal coverage criteria developed by the Company in consideration of peer-reviewed medical literature, clinical practice guidelines, regulatory status, and/or expert opinion. 

The Company reserves the right to reimburse only those services that are furnished in the most appropriate and cost-effective setting that is appropriate to the member’s medical needs and condition.

MEDICALLY NECESSARY

Chemical peels for the treatment of actinic keratoses are considered medically necessary and, therefore, covered without restrictions based on the lesion or an individual's characteristics.

Dermal chemical peels for the treatment of premalignant skin lesions other than actinic keratoses (e.g., actinic cheilitis, epidermodysplasia verruciformis) are considered medically necessary and, therefore, covered when both of the following criteria are met:
  • More than 10 lesions *(Waldman et al., 2017; Steeb et al., 2020; Eisen et al., 2021)
  • Topical 5-fluorouracil (5-FU) or imiquimod (Aldara) has been ineffective or contraindicated in treating the condition *(Waldman et al., 2017; Steeb et al., 2020; Eisen et al., 2021)
​NOT MEDICALLY NECESARY

​The use of epidermal chemical peels for the treatment of premalignant skin lesions other than actinic keratoses (e.g., actinic cheilitis, epidermodysplasia verruciformis) are considered not medically necessary and, therefore, not covered because the available published peer-reviewed literature does not support its use. *(Waldman et al., 2017; Steeb et al., 2020; Eisen et al., 2021)​​

COSMETIC

When performed as a cosmetic service, epidermal/dermal chemical peels for conditions including, but not limited to, wrinkles and photoaged skin are not covered by the Company because cosmetic services are not covered by Medicare. Therefore, they are not eligible for reimbursement consideration. *(Waldman et al., 2017; Steeb et al., 2020; Eisen et al., 2021)

REQUIRED DOCUMENTATION

The individual's medical record must reflect the medical necessity for the care provided. These medical records may include, but are not limited to: records from the professional provider's office, hospital, nursing home, home health agencies, therapies, and test reports.

The Company may conduct reviews and audits of services to our members, regardless of the participation status of the provider. All documentation is to be available to the Company upon request. Failure to produce the requested information may result in a denial for the service.

All requests for chemical peels require review by the Company and must include the following:
  • Photographs
  • Letter of medical necessity from the professional provider

Guidelines

This policy is consistent with Medicare's coverage determination. The Company's payment methodology may differ from Medicare.

BENEFIT APPLICATION

Subject to the terms and conditions of the applicable Evidence of Coverage, chemical peels for the treatment of actinic keratoses are covered under the medical benefits of the Company’s Medicare Advantage products when the medical necessity criteria listed in this medical policy are met.

Subject to the terms and conditions of the applicable Evidence of Coverage, dermal chemical peels for the treatment of premalignant​ skin lesions other than actinic keratoses ​​are covered under the medical benefits of the Company’s Medicare Advantage products when the medical necessity criteria listed in this medical policy are met.

Subject to the terms and conditions of the applicable Evidence of Coverage, epidermal chemical peels for the treatment of premalignant skin lesions other than actinic keratoses​ are not eligible for payment under the medical benefits of the Company’s Medicare Advantage products because the service is considered not medically necessary and, therefore, not covered.

Services that are cosmetic are excluded for the Company’s Medicare Advantage products because they are not covered by Medicare. Therefore, they are not eligible for reimbursement consideration.

Description

A chemical peel (chemexfoliation), also sometimes referred to as chemosurgery or dermapeeling, is the application of caustic material to the skin resulting in destruction of the epidermis and/or superficial dermis in whole or part.

The three main classifications of chemical peels are characterized by the depth of the tissue injury caused: superficial, medium, and deep. The depth of area of injury created by the peel is based on several factors including the type of chemical, the concentration of the chemical, number of applications, and the individual's skin type. 

Superficial chemical peels, sometimes referred to as epidermal peels, only penetrate the epidermis and therefore are used in indications affecting that layer (e.g., mild photoaging, melasma, and acne vulgaris). Common types of superficial peels are alpha hydroxy acids (AHAs), such as glycolic (30%–50%), lactic (10%–30%) or mandelic (40%); beta hydroxyl acids (BHAs), such as salicylic acid (30%); and alpha Misspelled Wordketo acids (AKAs), such as pyruvic acid (50%).​ This application is commonly used to treat fine or subtle lines, lighten skin due to hyperpigmentary disorders, and improve the skin's texture and appearance.

Medium-depth peels, sometimes referred to as dermal peels, penetrate the epidermis and the papillary dermis and therefore are used for indications affecting those layers (e.g., moderate photoaging, mild acne scars, and actinic keratoses​). Common types of medium-depth peels are salicylic acid (>30%, multilayer application), glycolic acid (70%, with or without pretreatment primer such as Jessner solution), trichloroacetic acid (TCA) (30%–50%, monolayer application, with or without pretreatment primer such as Jessner solution). Jessner solution is a primer used to optimize medium-depth peels by disrupting Misspelled Wordcornified layer (salicylic acid, 14g; resorcinol, 14g; lactic acid (85%), 14g; and ethanol to 100 mL). Chemical peels are appropriate when there are numerous lesions.

Deep peels, also sometimes referred to as dermal peels, penetrate the epidermis, papillary dermis, and midreticular dermis and therefore are used to treat indications affecting those layers (e.g., severe photoaging, deep acne scars, and premalignant skin neoplasms).​ Common types of deep chemical peels are TCA (>50%, monolayer application, with or without pretreatment primer such as Jessner solution), Baker-Gordon phenol peel (detergent, croton oil as an epidermolytic agent, phenol, and water for dilution to 50%–55% phenol).

Actinic keratoses are keratinocyte neoplasms that occur on skin that has had long-term sun exposure. Actinic keratoses are typically confined to the epidermis but can extend into the papillary dermis or reticular dermis, where they are termed as squamous cell carcinomas. The estimated progression of actinic keratoses to squamous cell carcinomas varies from 0.1% to 20%. Typical treatment options include topical creams, gels, and solutions; cryosurgery; and photodynamic therapy. Lee et al., writing in the Journal of the American Academy of Dermatology (2019), listed the indications for medium-depth peels and noted that its “penetration into the papillary dermis supports its use in the treatment of actinic keratoses.” ​

Cosmetic services are those provided to improve an individual's physical appearance, from which no significant improvement in physiologic function can be expected. Emotional and/or psychological improvement alone does not constitute improvement in physiologic function.

References

Alfaro OL, Alcala PD, Navarrete FG, et al. Effectiveness of Jessner's solution plus 35% trichloroacetic acid versus 5% 5-fluorouracil on multiple facial actinic keratosis. Dermatol Rev Mex. 2012;56:38-46.

American Society of Plastic Surgeons (ASPS). Chemical peel. [ASPS Web site]. Available at:  http://www.plasticsurgery.org/cosmetic-procedures/chemical-peel.html. Accessed October 15, 2025.

American Academy of Oral Medicine (AAOM). Solar cheilitis. [AAOM Web site]. 01/24/2008. Available at:  https://maaom.memberclicks.net/index.php?option=com_content&view=article&id=137:solar-cheilitis&catid=22:patient-condition-information&Itemid=120. Accessed October 15, 2025.

Berman B. Treatment of actinic keratosis. [UpToDate Web site]. 04/02/2025. Available at: Treatment of actinic keratosis - UpToDate [via subscription only]. Accessed October 15, 2025.

Brodland DG, Roenigk RK. Trichloroacetic acid chemexfoliation (chemical peel) for extensive premalignant actinic damage of the face and scalp. Mayo Clin Proc. 1988;63(9):887-896.

Centers for Medicare and Medicaid Services (CMS). National Coverage Determination (NCD). 250.4: Treatment of actinic keratosis (AKs). [CMS Web site]. 11/26/2001. Available at: http://www.cms.gov/medicare-coverage-database/details/ncd-details.aspx?NCDId=129&ncdver=1&NCAId=1&ver=20&NcaName=Actinic+Keratoses&bc=gEAAAAAAEAAA&. Accessed October 15, 2025.

Costa C, Scalvenzi M, Ayala F, et al. How to treat actinic keratosis? An update. J Dermatol Case Rep. 2015;9(2):29-35.

Di Nuzzo S, Cortelazzi C, Boccaletti V, et al. Comparative study of trichloroacetic acid vs. photodynamic therapy with topical 5-aminolevulinic acid for actinic keratosis of the scalp. Photodermatol Photoimmunol Photomed. 2015;31(5):233-8.
Eisen DB, Asgari MM, Bennett DD, et al. Guidelines of care for the management of actinic keratosis. J Am Acad Dermatol. 2021;85(4):e209-e233.

Gold MH, Nestor MS. Current treatments of actinic keratosis. J Drugs Dermatol. 2006;5(2 Suppl):17-25.

Holzer G, Pinkowicz A, Radakovic S, et al. Randomized controlled trial comparing 35% trichloroacetic acid peel and 5-aminolaevulinic acid photodynamic therapy for treating multiple actinic keratosis. Br J Dermatol. 2017;176(5):1155-1161.

Kaminaka C, Uede M, Matsunaka H, et al. Clinical evaluation of glycolic acid chemical peeling in patients with acne vulgaris: a randomized, double-blind, placebo-controlled, split-face comparative study. Dermatol Surg. 2014;40(3):314-22.

Kaminaka C, Yamamoto Y, Yonei N, et al. Phenol peels as a novel therapeutic approach for actinic keratosis and Bowen disease: prospective pilot trial with assessment of clinical, histologic, and immunohistochemical correlations. J Am Acad Dermatol. 2009;60(4):615-25.

Lawrence N, Cox SE, Cockerell CJ, et al. A comparison of the efficacy and safety of Jessner's solution and 35% trichloroacetic acid vs 5% fluorouracil in the treatment of widespread facial actinic keratoses. Arch Dermatol. 1995;131(2):176-81.

Lee KC, Wambier CG, Soon SL, et al. Basic chemical peeling: Superficial and medium-depth peels. J Am Acad Dermatol. 2019;81(2):313-324.

Lynch SA, Schwarz KA. Chapter 83: Chemical Peeling and Dermabrasion. Plastic Surgery Secrets Plus. 2nd ed. Mosby. 2010:549-553.

​Marrero GM, Katz BE. The new fluor-hydroxy pulse peel. A combination of 5-fluorouracil and glycolic acid. Dermatol Surg. 1998;24(9):973-8.

McIntyre WJ, Downs MR, Bedwell SA. Treatment options for actinic keratoses. Am Fam Physician. 2007;76(5):667-671.

Morganroth GS, Leffell DJ. Nonexcisional treatment of benign and premalignant cutaneous lesions. Clin Plast Surg. 1993;20(1):91-104.​

National Institutes of Health Genetic and Rare Diseases Information Center. Epidermodysplasia verruciformis. 02/2025. Available at: https://rarediseases.info.nih.gov/diseases/6357/epidermodysplasia-verruciformis​. Accessed October 15, 2025.

Nelson BR, Fader DJ, Gillard M, et al. Pilot histologic and ultrastructural study of the effects of medium-depth chemical facial peels on dermal collagen in patients with actinically damaged skin. J Am Acad Dermatol. 1995;32(3):472-478.

Padilla RS. Epidemiology, natural history, and diagnosis of actinic keratosis. [UpToDate Web site]. 09/09/2025. Available at https://www.uptodate.com/contents/epidemiology-natural-history-and-diagnosis-of-actinic-keratosis?search=actinic keratosis&source=search_result&selectedTitle=2~99&usage_type=default&display_rank=2 [via subscription only]. Accessed October 15, 2025.

​Padilla RS, Sebastian S, Jiang Z, et al. Gene expression patterns of normal human skin, actinic keratosis, and squamous cell carcinoma: a spectrum of disease progression. Arch Dermatol. 2010;146(3):288-93.

Purdy S, de Berker D. Acne vulgaris. BMJ Clin Evid. 2011; 2011.

Reynolds RV, Yeung H, Cheng CE, et al. Guidelines of care for the management of acne vulgaris. J Am Acad Dermatol. ​2024;90(5):1006.e1-1006.e30.​

Sandoval Osses M, Garcia-Huidobro Ramirez I, Molgo Novell M. Safety and effectiveness of the association of 5-fluorouracil and glycolic acid peeling for the treatment of multiple actinic keratoses. Piel. 2010;25:4-8.

Soleymani T, Lanoue J, Rahman Z. A Practical Approach to Chemical Peels: A Review of Fundamentals and Step-by-step Algorithmic Protocol for Treatment. J Clin Aesthet Dermatol. 2018;11(8):21-28.​

Steeb T, Koch EAT, Wessely A, et al. Chemical peelings for the treatment of actinic keratosis: a systematic review and meta-analysis. J Eur Acad Dermatol Venereol. 2021;35(3):641-649.

Strauss JS, Krowchuk DP, Leyden JJ, et al. Guidelines of care for acne vulgaris management. J Am Acad Dermatol. 2007;56(4):651-663.

Sumita JM, Miot HA, Soares JLM, et al. Tretinoin (0.05% cream vs. 5% peel) for photoaging and field cancerization of the forearms: randomized, evaluator-blinded, clinical trial. J Eur Acad Dermatol Venereol. 2018;32(10):1819-1826.

Taub AF. Procedural treatments for acne vulgaris. Dermatol Surg. 2007;33(9):1005-1026.

Van Scott EJ, Yu RJ. Alpha hydroxy acids: procedures for use in clinical practice. Cutis. 1989;43(3):222-228.

Waldman A, Bolotin D, Arndt KA, et al. ASDS Guidelines Task Force: Consensus Recommendations Regarding the Safety of Lasers, Dermabrasion, Chemical Peels, Energy Devices, and Skin Surgery During and After Isotretinoin Use. Dermatol Surg. 2017;43(10):1249-1262.

Witheiler DD, Lawrence N, Cox SE, et al. Long-term efficacy and safety of Jessner's solution and 35% trichloroacetic acid vs 5% fluorouracil in the treatment of widespread facial actinic keratoses. Dermatol Surg. 1997;23(3):191-196.​​

Coding

CPT Procedure Code Number(s)
MEDICALLY NECESSARY​

15789, 15793

NOT MEDICALLY NECESSARY

15788, 15792

ICD - 10 Procedure Code Number(s)
N/A

ICD - 10 Diagnosis Code Number(s)
B07.8 Other viral warts

L56.8 Other specified acute skin changes due to ultraviolet radiation

L57.0 Actinic keratosis

HCPCS Level II Code Number(s)
N/A

Revenue Code Number(s)
N/A



Coding and Billing Requirements


Policy History

12/29/2025
12/29/2025
MA11.103
Medical Policy Bulletin
Medicare Advantage
No